Phase 2 trial shows 83% of adults treated with survodutide achieve significant improvement in MASH
Up to 83.0% of adults treated with survodutide (Boehringer Ingelheim and Zealand Pharma) achieved a statistically significant improvement...
Phase 2 trial shows 83% of adults treated with survodutide achieve significant improvement in MASH
NICE approves endoscopic sleeve gastroplasty for weight loss management
Intraoperative leak tests correlated with increase in staple line leakage but a lower rate of postoperative bleeding
First procedures utilising ReShape’s next-generation Lap-Band 2.0 FLEX
Journal Watch 22/2/2024
Interdisciplinary therapy programme reduces inflammation and cardiometabolic risk in adolescents with obesity
Tranexamic acid results in better LSG outcomes compared to placebo